Johnson & Johnson (NYSE: JNJ) lifts 2026 outlook after $25.3B Q2 sales
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Johnson & Johnson reported second‑quarter 2026 sales of $25.3 billion, up 6.6% from 2025, with Innovative Medicine up 7.8% and MedTech up 4.5%. Net earnings were $5.53 billion and diluted EPS $2.27, compared with $2.29 a year earlier. On a non‑GAAP basis, adjusted net earnings rose to $7.08 billion and adjusted diluted EPS to $2.90, increases of 5.7% and 4.7%.
For the first six months of 2026, sales reached $49.4 billion, up 8.2%, while GAAP net earnings declined to $10.77 billion and EPS to $4.41. Adjusted diluted EPS for the period was $5.60, up 1.3%. Strong operational performance results in the company increasing 2026 guidance, now estimating reported sales of $100.8–$101.4 billion (midpoint $101.1 billion) and adjusted diluted EPS of $11.60–$11.75 (midpoint $11.68). The release also highlights recent approvals and data for products including TREMFYA, CAPLYTA and the Dual Energy THERMOCOOL SMARTTOUCH SF platform, along with broader Innovative Medicine and MedTech pipeline and investment activity.
Positive
- None.
Negative
- First‑half 2026 GAAP net earnings declined 34.9% to $10.77 billion, with diluted EPS falling 35.3% to $4.41 from $6.82 a year earlier.
Insights
Analyzing...
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Reported Sales: $25,310 million
Q2 2026 Net Earnings: $5,534 million
Q2 2026 Diluted EPS: $2.27
+5 more
8 metrics
Q2 2026 Reported Sales
$25,310 million
Worldwide sales to customers for the second quarter of 2026, up 6.6% versus 2025
Q2 2026 Net Earnings
$5,534 million
GAAP net earnings for the second quarter of 2026, a 0.1% decrease from 2025
Q2 2026 Diluted EPS
$2.27
GAAP diluted earnings per share for Q2 2026 versus $2.29 in Q2 2025
Q2 2026 Adjusted Diluted EPS
$2.90
Non-GAAP adjusted diluted EPS for Q2 2026, up 4.7% from $2.77 in 2025
Six‑Month 2026 Sales
$49,372 million
Sales to customers for the six months ended June 28, 2026, up 8.2% year over year
Six‑Month 2026 Net Earnings
$10,769 million
GAAP net earnings for the first six months of 2026, down 34.9% versus 2025
2026 Estimated Reported Sales Midpoint
$101.1 billion
Midpoint of 2026 reported sales guidance range $100.8B–$101.4B as of July 2026
2026 Adjusted EPS Guidance Midpoint
$11.68
Midpoint of 2026 adjusted diluted EPS guidance range $11.60–$11.75
Key Terms
operational sales growth, adjusted operational sales growth, In-process research and development impairments, effective tax rate, +1 more
5 terms
operational sales growth financial
"2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%"
adjusted operational sales growth financial
"with operational growth of 5.6% and adjusted operational growth of 5.7%"
In-process research and development impairments financial
"In-process research and development impairments | 36 | 0.1"
effective tax rate financial
"Effective tax rate | 18.0 % | | 14.7 %"
The effective tax rate is the percentage of a company's profits that it pays in taxes. It shows how much of its earnings go to taxes after all deductions and credits are considered. For investors, it indicates how much of the company's income is taken by taxes, impacting overall profitability and financial health.
Non-GAAP financial measures financial
""Non-GAAP financial measures" ... are non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Earnings Snapshot
Q2 2026 reported sales: $25,310 million · Guidance included
second quarter and six months ended June 28, 2026
Q2 2026 reported sales
$25,310 million
up 6.6% from Q2 2025
Q2 2026 GAAP diluted EPS
$2.27
down 0.9% from $2.29 in Q2 2025
Q2 2026 adjusted diluted EPS
$2.90
up 4.7% from $2.77 in Q2 2025
Six‑month 2026 sales
$49,372 million
up 8.2% from the first six months of 2025
Six‑month 2026 GAAP diluted EPS
$4.41
down 35.3% from $6.82 in 2025
Six‑month 2026 adjusted diluted EPS
$5.60
up 1.3% from $5.53 in 2025
Guidance
For 2026, the company guides to estimated reported sales of $100.8–$101.4 billion (midpoint $101.1 billion) and adjusted diluted EPS of $11.60–$11.75 (midpoint $11.68).
FAQ
How did Johnson & Johnson (JNJ) perform financially in Q2 2026?
Johnson & Johnson reported Q2 2026 sales of $25.3 billion, up 6.6% year over year. GAAP net earnings were $5.53 billion with diluted EPS of $2.27, while adjusted diluted EPS increased to $2.90, up 4.7% versus 2025.
What 2026 guidance did Johnson & Johnson (JNJ) provide in July 2026?
The company guides 2026 estimated reported sales to $100.8–$101.4 billion, midpoint $101.1 billion. It expects adjusted diluted EPS of $11.60–$11.75, midpoint $11.68, and adjusted operational EPS of $11.50–$11.65 with a 7.3% midpoint growth versus the prior year.
How did Johnson & Johnson’s (JNJ) Innovative Medicine and MedTech segments perform in Q2 2026?
In Q2 2026, Innovative Medicine sales were $16.38 billion, up 7.8% reported. MedTech sales reached $8.93 billion, up 4.5%. Both segments contributed to worldwide sales of $25.31 billion, with operational growth of 5.6% and adjusted operational growth of 5.7%.
What were Johnson & Johnson’s (JNJ) first‑half 2026 results compared with 2025?
For the six months ended June 28, 2026, sales were $49.37 billion, up 8.2% from 2025. GAAP net earnings were $10.77 billion versus $16.54 billion, and diluted EPS was $4.41 versus $6.82, while adjusted diluted EPS rose slightly to $5.60 from $5.53.
How do Johnson & Johnson’s (JNJ) GAAP and non-GAAP EPS compare in Q2 2026?
In Q2 2026, GAAP diluted EPS was $2.27, down from $2.29 a year earlier. Non‑GAAP adjusted diluted EPS was $2.90, up from $2.77, reflecting exclusions for intangible amortization, litigation, restructuring, Orthopaedics separation and other specified special items.
What geographic trends did Johnson & Johnson (JNJ) report for Q2 2026?
Q2 2026 U.S. sales were $14.53 billion, up 7.3% year over year. International sales were $10.78 billion, up 5.7%. Worldwide sales of $25.31 billion reflected 5.6% operational growth and a 1.0‑point favorable currency impact on a reported basis.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 2.02 Results of operations and financial condition
On July 15, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 28, 2026.
Item 9.01 Financial statements and exhibits
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |||||||
99.1 | Press Release dated July 15, 2026 for the period ended June 28, 2026 | |||||||
99.2 | Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal second quarter and six months | |||||||
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. | |||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 15, 2026
| JOHNSON & JOHNSON | |||||
(Registrant) | |||||
By: | /s/ Robert J. Decker, Jr. | ||||
Robert J. Decker, Jr. Controller (Principal Accounting Officer) | |||||
Exhibit 99.1
Media contact: media-relations@its.jnj.com | Investor contact: investor-relations@its.jnj.com | |||||||
For immediate release
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
•2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%*
•2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90
•Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint
•Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, CAPLYTA for the prevention of relapse in schizophrenia, and Dual Energy THERMOCOOL SMARTTOUCH SF platform; fortifying future with data from RYBREVANT FASPRO in advanced head and neck cancer, TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma, and OTTAVA in upper abdominal procedures
New Brunswick, N.J. (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”
Overall financial results
Q2 | ||||||||||||||||||||
($ in Millions, except EPS) | 2026 | 2025 | % Change | |||||||||||||||||
Reported Sales | $25,310 | $23,743 | 6.6% | |||||||||||||||||
Net Earnings | $5,534 | $5,537 | -0.1% | |||||||||||||||||
EPS (diluted) | $2.27 | $2.29 | -0.9% | |||||||||||||||||
Q2 | ||||||||||||||||||||
Non-GAAP* ($ in Millions, except EPS) | 2026 | 2025 | % Change | |||||||||||||||||
Operational Sales1,2 | 5.6% | |||||||||||||||||||
Adjusted Operational Sales1,3 | 5.7% | |||||||||||||||||||
Adjusted Net Earnings1,4 | $7,081 | $6,699 | 5.7% | |||||||||||||||||
Adjusted EPS (diluted)1,4 | $2.90 | $2.77 | 4.7% | |||||||||||||||||
Free Cash Flow5,6 | ~$8,700 | $6,214 | ||||||||||||||||||
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
4Excludes intangible amortization expense and special items
5Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
6Second-quarter YTD 2026 is estimated as of July 15, 2026
Note: values may have been rounded
Regional sales results
Q2 | % Change | |||||||||||||||||||
($ in Millions) | 2026 | 2025 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 | ||||||||||||||
U.S. | $14,533 | $13,544 | 7.3% | 7.3 | - | 7.4 | ||||||||||||||
International | 10,777 | 10,199 | 5.7 | 3.4 | 2.3 | 3.5 | ||||||||||||||
Worldwide | $25,310 | $23,743 | 6.6% | 5.6 | 1.0 | 5.7 | ||||||||||||||
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q2 | % Change | |||||||||||||||||||
($ in Millions) | 2026 | 2025 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 | ||||||||||||||
Innovative Medicine | $16,384 | $15,202 | 7.8% | 6.8 | 1.0 | 6.9 | ||||||||||||||
MedTech | 8,926 | 8,541 | 4.5 | 3.6 | 0.9 | 3.7 | ||||||||||||||
Worldwide | $25,310 | $23,743 | 6.6% | 5.6 | 1.0 | 5.7 | ||||||||||||||
1Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2Excludes the impact of translational currency
3Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Second-Quarter 2026 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 6.8%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 760 basis points impact) and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology.
MedTech
MedTech worldwide operational sales grew 3.6%*, with net acquisitions and divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by wound closure products and biosurgery products in Surgery, electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.
Full-year 2026 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) | July 2026 | April 2026 | ||||||
Adjusted Operational Sales1,2 Change vs. Prior Year / Mid-point | 6.2% – 6.8% / 6.5% | 5.6% – 6.6% / 6.1% | ||||||
Operational Sales2 / Mid-point Change vs. Prior Year / Mid-point | $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8% | $99.7B – $100.7B / $100.2B 5.9% – 6.9% / 6.4% | ||||||
Estimated Reported Sales3/ Mid-point Change vs. Prior Year / Mid-point | $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3% | $100.3B – $101.3B / $100.8B 6.5% – 7.5% / 7.0% | ||||||
Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $11.50 – $11.65 / $11.58 6.6% – 8.0% / 7.3% | $11.30 – $11.50 / $11.40 4.7% – 6.7% / 5.7% | ||||||
Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point | $11.60 – $11.75 / $11.68 7.5% – 8.9% / 8.2% | $11.45 – $11.65 / $11.55 6.1% – 8.1% / 7.1% | ||||||
1Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2Non-GAAP financial measure; excludes the impact of translational currency
3Calculated using Euro Average Rate: July 2026 = $1.15 and April 2026 = $1.17 (Illustrative purposes only)
4Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and www.factsabouttalc.com.
Regulatory | Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform1 | Press Release | |||||||||
CHMP recommendation advances Johnson & Johnson’s TECVAYLI (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma | Press Release | ||||||||||
FDA approves label expansion, cementing TREMFYA as the only IL‑23 inhibitor proven to help stop further joint damage | Press Release | ||||||||||
FDA approves CAPLYTA (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia | Press Release | ||||||||||
Johnson & Johnson Announces CE Mark Approval for the New ETHICON 4000 Stapler | Press Release | ||||||||||
FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA) | Press Release | ||||||||||
Data Releases | Johnson & Johnson presents new IMAAVY (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis | Press Release | |||||||||
New TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma | Press Release | ||||||||||
IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies | Press Release | ||||||||||
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study | Press Release | ||||||||||
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease | Press Release | ||||||||||
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited | Press Release | ||||||||||
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm | Press Release | ||||||||||
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer | Press Release | ||||||||||
New TECVAYLI (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma | Press Release | ||||||||||
Johnson & Johnson study shows TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease | Press Release | ||||||||||
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease | Press Release | ||||||||||
Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System | Press Release | ||||||||||
CAPLYTA (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis | Press Release | ||||||||||
IMAAVY (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) | Press Release | ||||||||||
Product Launch | Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter | Press Release | |||||||||
Other | DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer1 | Press Release | |||||||||
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida | Press Release | ||||||||||
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients | Press Release | ||||||||||
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform | Press Release | ||||||||||
DePuy Synthes Announces Agreement to Acquire Miniature Radiofrequency Tracking Technology Across its Joint Reconstruction Portfolio | Press Release | ||||||||||
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS | Press Release | ||||||||||
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation | Press Release | ||||||||||
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations | Press Release | ||||||||||
Johnson & Johnson Launches Landmark Head-to-Head Pulsed Field Ablation Trial in Persistent Atrial Fibrillation | Press Release | ||||||||||
Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026 | Press Release | ||||||||||
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Exhibit 99.2
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | SECOND QUARTER | |||||||||||||||||||
| Percent Change | ||||||||||||||||||||
| Sales to customers by geographic area | 2026 | 2025 | Total | Operations | Currency | |||||||||||||||
U.S. | $14,533 | 13,544 | 7.3 | % | 7.3 | — | ||||||||||||||
Europe | 5,726 | 5,387 | 6.3 | 3.3 | 3.0 | |||||||||||||||
Western Hemisphere excluding U.S. | 1,309 | 1,206 | 8.5 | 2.7 | 5.8 | |||||||||||||||
Asia-Pacific, Africa | 3,742 | 3,606 | 3.8 | 3.9 | (0.1) | |||||||||||||||
International | 10,777 | 10,199 | 5.7 | 3.4 | 2.3 | |||||||||||||||
Worldwide | $25,310 | 23,743 | 6.6 | % | 5.6 | 1.0 | ||||||||||||||
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | SIX MONTHS | ||||||||||||||||
| Percent Change | |||||||||||||||||
| Sales to customers by geographic area | 2026 | 2025 | Total | Operations | Currency | ||||||||||||
U.S. | $27,863 | 25,849 | 7.8 | % | 7.8 | — | |||||||||||
Europe | 11,574 | 10,497 | 10.3 | 3.0 | 7.3 | ||||||||||||
Western Hemisphere excluding U.S. | 2,602 | 2,373 | 9.6 | 2.6 | 7.0 | ||||||||||||
Asia-Pacific, Africa | 7,333 | 6,917 | 6.0 | 4.9 | 1.1 | ||||||||||||
International | 21,509 | 19,787 | 8.7 | 3.6 | 5.1 | ||||||||||||
Worldwide | $49,372 | 45,636 | 8.2 | % | 6.0 | 2.2 | |||||||||||
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | SECOND QUARTER | |||||||||||||||||||
| Percent Change | ||||||||||||||||||||
| Sales to customers by segment of business | 2026 | 2025 | Total | Operations | Currency | |||||||||||||||
Innovative Medicine | ||||||||||||||||||||
U.S. | $ | 9,979 | 9,161 | 8.9 | % | 8.9 | — | |||||||||||||
International | 6,405 | 6,041 | 6.0 | 3.6 | 2.4 | |||||||||||||||
| 16,384 | 15,202 | 7.8 | 6.8 | 1.0 | ||||||||||||||||
MedTech | ||||||||||||||||||||
U.S. | 4,554 | 4,383 | 3.9 | 3.9 | — | |||||||||||||||
International | 4,372 | 4,158 | 5.2 | 3.2 | 2.0 | |||||||||||||||
| 8,926 | 8,541 | 4.5 | 3.6 | 0.9 | ||||||||||||||||
U.S. | 14,533 | 13,544 | 7.3 | 7.3 | — | |||||||||||||||
International | 10,777 | 10,199 | 5.7 | 3.4 | 2.3 | |||||||||||||||
Worldwide | $ | 25,310 | 23,743 | 6.6 | % | 5.6 | 1.0 | |||||||||||||
Johnson & Johnson and subsidiaries
Supplementary sales data
| (Unaudited; Dollars in Millions) | SIX MONTHS | |||||||||||||||||||
| Percent Change | ||||||||||||||||||||
| Sales to customers by segment of business | 2026 | 2025 | Total | Operations | Currency | |||||||||||||||
Innovative Medicine | ||||||||||||||||||||
U.S. | $ | 18,850 | 17,253 | 9.3 | % | 9.3 | — | |||||||||||||
International | 12,960 | 11,822 | 9.6 | 3.9 | 5.7 | |||||||||||||||
| 31,810 | 29,075 | 9.4 | 7.1 | 2.3 | ||||||||||||||||
MedTech | ||||||||||||||||||||
U.S. | 9,013 | 8,596 | 4.8 | 4.8 | — | |||||||||||||||
International | 8,549 | 7,965 | 7.3 | 3.2 | 4.1 | |||||||||||||||
| 17,562 | 16,561 | 6.0 | 4.1 | 1.9 | ||||||||||||||||
U.S. | 27,863 | 25,849 | 7.8 | 7.8 | — | |||||||||||||||
International | 21,509 | 19,787 | 8.7 | 3.6 | 5.1 | |||||||||||||||
Worldwide | $ | 49,372 | 45,636 | 8.2 | % | 6.0 | 2.2 | |||||||||||||
Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
| (Unaudited; in Millions Except Per Share Figures) | SECOND QUARTER | |||||||||||||||||||
| 2026 | 2025 | Percent Increase (Decrease) | ||||||||||||||||||
| Amount | Percent to Sales | Amount | Percent to Sales | |||||||||||||||||
| Sales to customers | $ | 25,310 | 100.0 | $ | 23,743 | 100.0 | 6.6 | |||||||||||||
| Cost of products sold | 8,051 | 31.8 | 7,628 | 32.1 | 5.5 | |||||||||||||||
| Gross Profit | 17,259 | 68.2 | 16,115 | 67.9 | 7.1 | |||||||||||||||
| Selling, marketing and administrative expenses | 6,432 | 25.4 | 5,889 | 24.8 | 9.2 | |||||||||||||||
| Research and development expense | 3,653 | 14.4 | 3,516 | 14.8 | 3.9 | |||||||||||||||
| Interest (income) expense, net | 62 | 0.2 | 48 | 0.2 | ||||||||||||||||
| Other (income) expense, net | 331 | 1.3 | 107 | 0.5 | ||||||||||||||||
| Restructuring | 34 | 0.2 | 64 | 0.3 | ||||||||||||||||
| Earnings before provision for taxes on income | 6,747 | 26.7 | 6,491 | 27.3 | 3.9 | |||||||||||||||
| Provision for taxes on income | 1,213 | 4.8 | 954 | 4.0 | 27.1 | |||||||||||||||
| Net earnings | $ | 5,534 | 21.9 | $ | 5,537 | 23.3 | (0.1) | |||||||||||||
| Net earnings per share (Diluted) | $ | 2.27 | $ | 2.29 | (0.9) | |||||||||||||||
| Average shares outstanding (Diluted) | 2,440.1 | 2,419.1 | ||||||||||||||||||
| Effective tax rate | 18.0 | % | 14.7 | % | ||||||||||||||||
Adjusted earnings before provision for taxes and net earnings (1) (A) | ||||||||||||||||||||
Earnings before provision for taxes on income | $ | 8,660 | 34.2 | $ | 8,188 | 34.5 | 5.8 | |||||||||||||
Net earnings | $ | 7,081 | 28.0 | $ | 6,699 | 28.2 | 5.7 | |||||||||||||
Net earnings per share (Diluted) | $ | 2.90 | $ | 2.77 | 4.7 | |||||||||||||||
Effective tax rate | 18.2 | % | 18.2 | % | ||||||||||||||||
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
Johnson & Johnson and subsidiaries
Condensed consolidated statement of earnings
| (Unaudited; in Millions Except Per Share Figures) | SIX MONTHS | ||||||||||||||||
| 2026 | 2025 | Percent Increase (Decrease) | |||||||||||||||
| Amount | Percent to Sales | Amount | Percent to Sales | ||||||||||||||
| Sales to customers | $ | 49,372 | 100.0 | $ | 45,636 | 100.0 | 8.2 | ||||||||||
| Cost of products sold | 16,157 | 32.7 | 14,985 | 32.8 | 7.8 | ||||||||||||
| Gross Profit | 33,215 | 67.3 | 30,651 | 67.2 | 8.4 | ||||||||||||
| Selling, marketing and administrative expenses | 12,466 | 25.3 | 11,001 | 24.1 | 13.3 | ||||||||||||
| Research and development expense | 7,180 | 14.5 | 6,741 | 14.8 | 6.5 | ||||||||||||
| In-process research and development impairments | 36 | 0.1 | — | — | |||||||||||||
| Interest (income) expense, net | 105 | 0.2 | (80) | (0.2) | |||||||||||||
| Other (income) expense, net | 625 | 1.3 | (7,214) | (15.8) | |||||||||||||
| Restructuring | 66 | 0.1 | 81 | 0.2 | |||||||||||||
| Earnings before provision for taxes on income | 12,737 | 25.8 | 20,122 | 44.1 | (36.7) | ||||||||||||
| Provision for taxes on income | 1,968 | 4.0 | 3,586 | 7.9 | (45.1) | ||||||||||||
| Net earnings | $ | 10,769 | 21.8 | $ | 16,536 | 36.2 | (34.9) | ||||||||||
| Net earnings per share (Diluted) | $ | 4.41 | $ | 6.82 | (35.3) | ||||||||||||
| Average shares outstanding (Diluted) | 2,443.9 | 2,423.3 | |||||||||||||||
| Effective tax rate | 15.5 | % | 17.8 | % | |||||||||||||
Adjusted earnings before provision for taxes and net earnings (1) (A) | |||||||||||||||||
Earnings before provision for taxes on income | $ | 16,481 | 33.4 | $ | 16,199 | 35.5 | 1.7 | ||||||||||
Net earnings | $ | 13,695 | 27.7 | $ | 13,405 | 29.4 | 2.2 | ||||||||||
Net earnings per share (Diluted) | $ | 5.60 | $ | 5.53 | 1.3 | ||||||||||||
Effective tax rate | 16.9 | % | 17.2 | % | |||||||||||||
(1) See Reconciliation of Non-GAAP Financial Measures.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
| SECOND QUARTER | SIX MONTHS | |||||||||||||||||||||||||
| (Dollars in Millions Except Per Share Data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| Net Earnings, after tax- as reported | $5,534 | $5,537 | $10,769 | $16,536 | ||||||||||||||||||||||
| Pre-tax Adjustments | ||||||||||||||||||||||||||
| Litigation related | 267 | 57 | 597 | (6,909) | ||||||||||||||||||||||
| Intangible Asset Amortization expense | 1,245 | 1,267 | 2,492 | 2,387 | ||||||||||||||||||||||
Restructuring related 1 | 276 | 79 | 338 | 134 | ||||||||||||||||||||||
| Orthopaedics separation related | 258 | — | 377 | — | ||||||||||||||||||||||
| Acquisition, integration and divestiture related | 80 | 246 | 176 | 378 | ||||||||||||||||||||||
| (Gains)/losses on securities | (213) | 21 | (272) | 60 | ||||||||||||||||||||||
| IPR&D impairments | — | — | 36 | — | ||||||||||||||||||||||
| Other | — | 27 | — | 27 | ||||||||||||||||||||||
| Tax Adjustments | ||||||||||||||||||||||||||
Tax impact on special item adjustments 2 | (368) | (321) | (792) | 994 | ||||||||||||||||||||||
| Tax legislation and other tax related | 2 | (214) | (26) | (202) | ||||||||||||||||||||||
| Adjusted Net Earnings , after tax | $7,081 | $6,699 | $13,695 | $13,405 | ||||||||||||||||||||||
| Average shares outstanding (Diluted) | 2,440.1 | 2,419.1 | 2,443.9 | 2,423.3 | ||||||||||||||||||||||
| Adjusted net earnings per share (Diluted) | $2.90 | $2.77 | $5.60 | $5.53 | ||||||||||||||||||||||
| Operational adjusted net earnings per share (Diluted) | $2.86 | $5.43 | ||||||||||||||||||||||||
Notes:
1In the fiscal second quarter of 2026, the Company commenced a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of 2026.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $59 million were recorded in the fiscal second quarter of 2026 ($114 million Q2 2026 YTD) and $29 million in the fiscal second quarter of 2025 ($29 million Q2 2025 YTD) and primarily include costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $17 million in the fiscal second quarter of 2026 ($24 million Q2 2026 YTD) and $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.
2The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Second quarter 2026 actual vs. 2025 actual
| Segments | ||||||||||||||||||||||||||
| Innovative Medicine | MedTech | Total | ||||||||||||||||||||||||
| WW As Reported | 7.8 | % | 4.5 | % | 6.6 | % | ||||||||||||||||||||
| U.S. | 8.9 | % | 3.9 | % | 7.3 | % | ||||||||||||||||||||
| International | 6.0 | % | 5.2 | % | 5.7 | % | ||||||||||||||||||||
| WW Currency | 1.0 | 0.9 | 1.0 | |||||||||||||||||||||||
| U.S. | — | — | — | |||||||||||||||||||||||
| International | 2.4 | 2.0 | 2.3 | |||||||||||||||||||||||
| WW Operational | 6.8 | % | 3.6 | % | 5.6 | % | ||||||||||||||||||||
| U.S. | 8.9 | % | 3.9 | % | 7.3 | % | ||||||||||||||||||||
| International | 3.6 | % | 3.2 | % | 3.4 | % | ||||||||||||||||||||
| All Other Acquisitions and Divestitures (A&D) | 0.1 | 0.1 | 0.1 | |||||||||||||||||||||||
| U.S. | 0.0 | 0.2 | 0.1 | |||||||||||||||||||||||
| International | 0.2 | 0.0 | 0.1 | |||||||||||||||||||||||
| WW Adjusted Operational Ex A&D | 6.9 | % | 3.7 | % | 5.7 | % | ||||||||||||||||||||
| U.S. | 8.9 | % | 4.1 | % | 7.4 | % | ||||||||||||||||||||
| International | 3.8 | % | 3.2 | % | 3.5 | % | ||||||||||||||||||||
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
Johnson & Johnson and subsidiaries
Reconciliation of non-GAAP financial measures
Adjusted operational sales growth(A)
Six months 2026 actual vs. 2025 actual
| Segments | ||||||||||||||||||||
| Innovative Medicine | MedTech | Total | ||||||||||||||||||
| WW As Reported | 9.4 | % | 6.0 | % | 8.2 | % | ||||||||||||||
| U.S. | 9.3 | % | 4.8 | % | 7.8 | % | ||||||||||||||
| International | 9.6 | % | 7.3 | % | 8.7 | % | ||||||||||||||
| WW Currency | 2.3 | 1.9 | 2.2 | |||||||||||||||||
| U.S. | — | — | — | |||||||||||||||||
| International | 5.7 | 4.1 | 5.1 | |||||||||||||||||
| WW Operational | 7.1 | % | 4.1 | % | 6.0 | % | ||||||||||||||
| U.S. | 9.3 | % | 4.8 | % | 7.8 | % | ||||||||||||||
| International | 3.9 | % | 3.2 | % | 3.6 | % | ||||||||||||||
| Caplyta | (0.9) | (0.6) | ||||||||||||||||||
| U.S. | (1.6) | (1.0) | ||||||||||||||||||
| International | 0.0 | 0.0 | ||||||||||||||||||
| All Other Acquisitions and Divestitures (A&D) | 0.0 | 0.1 | 0.1 | |||||||||||||||||
| U.S. | 0.0 | 0.2 | 0.1 | |||||||||||||||||
| International | 0.2 | 0.0 | 0.1 | |||||||||||||||||
| WW Adjusted Operational Ex A&D | 6.2 | % | 4.2 | % | 5.5 | % | ||||||||||||||
| U.S. | 7.7 | % | 5.0 | % | 6.9 | % | ||||||||||||||
| International | 4.1 | % | 3.2 | % | 3.7 | % | ||||||||||||||
Note: Percentages are based on actual, non-rounded figures and may not sum
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SECOND QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2) | |||||||||||||||||||||||
| ONCOLOGY | |||||||||||||||||||||||
| US | $ | 4,069 | 3,385 | 20.3 | % | 20.3 | % | — | % | ||||||||||||||
| Intl | 3,337 | 2,928 | 14.0 | 11.2 | 2.8 | ||||||||||||||||||
| WW | 7,406 | 6,312 | 17.3 | 16.1 | 1.2 | ||||||||||||||||||
| DARZALEX | |||||||||||||||||||||||
| US | 2,435 | 2,017 | 20.7 | 20.7 | — | ||||||||||||||||||
| Intl | 1,772 | 1,521 | 16.4 | 13.5 | 2.9 | ||||||||||||||||||
| WW | 4,207 | 3,539 | 18.9 | 17.6 | 1.3 | ||||||||||||||||||
| CARVYKTI | |||||||||||||||||||||||
| US | 472 | 358 | 31.7 | 31.7 | — | ||||||||||||||||||
| Intl | 185 | 81 | * | * | * | ||||||||||||||||||
| WW | 657 | 439 | 49.4 | 47.7 | 1.7 | ||||||||||||||||||
| TECVAYLI | |||||||||||||||||||||||
| US | 186 | 114 | 63.9 | 63.9 | — | ||||||||||||||||||
| Intl | 74 | 52 | 40.7 | 39.2 | 1.5 | ||||||||||||||||||
| WW | 260 | 166 | 56.5 | 56.1 | 0.4 | ||||||||||||||||||
| TALVEY | |||||||||||||||||||||||
| US | 112 | 82 | 36.2 | 36.2 | — | ||||||||||||||||||
| Intl | 62 | 24 | * | * | * | ||||||||||||||||||
| WW | 174 | 106 | 63.3 | 62.6 | 0.7 | ||||||||||||||||||
| RYBREVANT / LAZCLUZE | |||||||||||||||||||||||
| US | 190 | 139 | 36.8 | 36.8 | — | ||||||||||||||||||
| Intl | 99 | 41 | * | * | * | ||||||||||||||||||
| WW | 289 | 179 | 60.8 | 61.6 | (0.8) | ||||||||||||||||||
| ERLEADA | |||||||||||||||||||||||
| US | 396 | 378 | 4.7 | 4.7 | — | ||||||||||||||||||
| Intl | 599 | 530 | 12.9 | 9.7 | 3.2 | ||||||||||||||||||
| WW | 995 | 908 | 9.5 | 7.6 | 1.9 | ||||||||||||||||||
| IMBRUVICA | |||||||||||||||||||||||
| US | 149 | 239 | (37.6) | (37.6) | — | ||||||||||||||||||
| Intl | 449 | 496 | (9.5) | (11.8) | 2.3 | ||||||||||||||||||
| WW | 599 | 735 | (18.6) | (20.2) | 1.6 | ||||||||||||||||||
OTHER ONCOLOGY(3) | |||||||||||||||||||||||
| US | 131 | 56 | * | * | — | ||||||||||||||||||
| Intl | 97 | 181 | (46.5) | (45.7) | (0.8) | ||||||||||||||||||
| WW | 226 | 238 | (4.6) | (3.9) | (0.7) | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SECOND QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| IMMUNOLOGY | |||||||||||||||||||||||
| US | $ | 2,372 | 2,505 | (5.3) | % | (5.3) | % | — | % | ||||||||||||||
| Intl | 1,473 | 1,489 | (1.0) | (3.5) | 2.5 | ||||||||||||||||||
| WW | 3,844 | 3,993 | (3.7) | (4.6) | 0.9 | ||||||||||||||||||
| TREMFYA | |||||||||||||||||||||||
| US | 1,465 | 796 | 84.2 | 84.2 | — | ||||||||||||||||||
| Intl | 581 | 391 | 48.7 | 44.2 | 4.5 | ||||||||||||||||||
| WW | 2,046 | 1,186 | 72.5 | 71.0 | 1.5 | ||||||||||||||||||
| SIMPONI / SIMPONI ARIA | |||||||||||||||||||||||
| US | 260 | 305 | (14.6) | (14.6) | — | ||||||||||||||||||
| Intl | 358 | 387 | (7.3) | (9.5) | 2.2 | ||||||||||||||||||
| WW | 618 | 690 | (10.5) | (11.7) | 1.2 | ||||||||||||||||||
| REMICADE | |||||||||||||||||||||||
| US | 215 | 283 | (24.1) | (24.1) | — | ||||||||||||||||||
US Exports(4) | 10 | 34 | (71.0) | (71.0) | — | ||||||||||||||||||
| Intl | 112 | 138 | (18.4) | (20.5) | 2.1 | ||||||||||||||||||
| WW | 338 | 455 | (25.8) | (26.4) | 0.6 | ||||||||||||||||||
| STELARA | |||||||||||||||||||||||
| US | 336 | 1,078 | (68.8) | (68.8) | — | ||||||||||||||||||
| Intl | 404 | 575 | (29.7) | (31.1) | 1.4 | ||||||||||||||||||
| WW | 740 | 1,653 | (55.2) | (55.7) | 0.5 | ||||||||||||||||||
| OTHER IMMUNOLOGY | |||||||||||||||||||||||
| US | 85 | 8 | * | * | — | ||||||||||||||||||
| Intl | 18 | 0 | * | * | * | ||||||||||||||||||
| WW | 104 | 8 | * | * | * | ||||||||||||||||||
| NEUROSCIENCE | |||||||||||||||||||||||
| US | 1,659 | 1,377 | 20.5 | 20.5 | — | ||||||||||||||||||
| Intl | 678 | 674 | 0.6 | (1.1) | 1.7 | ||||||||||||||||||
| WW | 2,337 | 2,051 | 14.0 | 13.4 | 0.6 | ||||||||||||||||||
| SPRAVATO | |||||||||||||||||||||||
| US | 514 | 366 | 40.7 | 40.7 | — | ||||||||||||||||||
| Intl | 70 | 50 | 41.2 | 34.7 | 6.5 | ||||||||||||||||||
| WW | 584 | 414 | 40.8 | 40.0 | 0.8 | ||||||||||||||||||
| CAPLYTA | |||||||||||||||||||||||
| US | 361 | 211 | 70.9 | 70.9 | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 361 | 211 | 70.9 | 70.9 | — | ||||||||||||||||||
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | |||||||||||||||||||||||
| US | 738 | 732 | 0.8 | 0.8 | — | ||||||||||||||||||
| Intl | 278 | 260 | 6.6 | 5.1 | 1.5 | ||||||||||||||||||
| WW | 1,015 | 992 | 2.3 | 1.9 | 0.4 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SECOND QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| CONCERTA / methylphenidate | |||||||||||||||||||||||
| US | $ | 12 | 24 | (48.6) | % | (48.6) | % | — | % | ||||||||||||||
| Intl | 133 | 139 | (4.2) | (4.8) | 0.6 | ||||||||||||||||||
| WW | 146 | 164 | (10.8) | (11.3) | 0.5 | ||||||||||||||||||
| OTHER NEUROSCIENCE | |||||||||||||||||||||||
| US | 34 | 45 | (22.9) | (22.9) | — | ||||||||||||||||||
| Intl | 198 | 226 | (12.3) | (13.7) | 1.4 | ||||||||||||||||||
| WW | 232 | 270 | (14.0) | (15.2) | 1.2 | ||||||||||||||||||
| PULMONARY HYPERTENSION (PH) | |||||||||||||||||||||||
| US | 814 | 799 | 1.8 | 1.8 | — | ||||||||||||||||||
| Intl | 329 | 314 | 4.9 | 3.4 | 1.5 | ||||||||||||||||||
| WW | 1,143 | 1,113 | 2.6 | 2.2 | 0.4 | ||||||||||||||||||
| UPTRAVI | |||||||||||||||||||||||
| US | 386 | 382 | 1.0 | 1.0 | — | ||||||||||||||||||
| Intl | 108 | 94 | 15.0 | 10.1 | 4.9 | ||||||||||||||||||
| WW | 494 | 476 | 3.8 | 2.8 | 1.0 | ||||||||||||||||||
| OPSUMIT / OPSYNVI | |||||||||||||||||||||||
| US | 416 | 403 | 3.2 | 3.2 | — | ||||||||||||||||||
| Intl | 187 | 180 | 3.9 | 3.6 | 0.3 | ||||||||||||||||||
| WW | 602 | 582 | 3.4 | 3.3 | 0.1 | ||||||||||||||||||
| OTHER PULMONARY HYPERTENSION | |||||||||||||||||||||||
| US | 13 | 16 | (16.9) | (16.9) | — | ||||||||||||||||||
| Intl | 34 | 40 | (14.3) | (12.7) | (1.6) | ||||||||||||||||||
| WW | 47 | 55 | (15.0) | (13.9) | (1.1) | ||||||||||||||||||
| INFECTIOUS DISEASES (ID) | |||||||||||||||||||||||
| US | 300 | 320 | (6.3) | (6.3) | — | ||||||||||||||||||
| Intl | 463 | 484 | (4.1) | (6.2) | 2.1 | ||||||||||||||||||
| WW | 763 | 803 | (5.0) | (6.3) | 1.3 | ||||||||||||||||||
| EDURANT / rilpivirine | |||||||||||||||||||||||
| US | 3 | 6 | (49.6) | (49.6) | — | ||||||||||||||||||
| Intl | 347 | 354 | (1.9) | (3.8) | 1.9 | ||||||||||||||||||
| WW | 350 | 360 | (2.7) | (4.6) | 1.9 | ||||||||||||||||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||||||||||||||
| US | 296 | 312 | (5.1) | (5.1) | — | ||||||||||||||||||
| Intl | 76 | 85 | (10.4) | (12.8) | 2.4 | ||||||||||||||||||
| WW | 372 | 396 | (6.3) | (6.8) | 0.5 | ||||||||||||||||||
| OTHER INFECTIOUS DISEASES | |||||||||||||||||||||||
| US | 1 | 2 | (47.9) | (47.9) | — | ||||||||||||||||||
| Intl | 40 | 45 | (9.6) | (12.8) | 3.2 | ||||||||||||||||||
| WW | 41 | 47 | (11.6) | (14.6) | 3.0 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SECOND QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| CARDIOVASCULAR / METABOLISM / OTHER (CVM) | |||||||||||||||||||||||
| US | $ | 765 | 776 | (1.3) | % | (1.3) | % | — | % | ||||||||||||||
| Intl | 124 | 154 | (19.4) | (21.5) | 2.1 | ||||||||||||||||||
| WW | 889 | 930 | (4.3) | (4.7) | 0.4 | ||||||||||||||||||
| XARELTO | |||||||||||||||||||||||
| US | 664 | 621 | 7.1 | 7.1 | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 664 | 621 | 7.1 | 7.1 | — | ||||||||||||||||||
| OTHER | |||||||||||||||||||||||
| US | 101 | 155 | (35.0) | (35.0) | — | ||||||||||||||||||
| Intl | 124 | 154 | (19.4) | (21.5) | 2.1 | ||||||||||||||||||
| WW | 225 | 309 | (27.2) | (28.3) | 1.1 | ||||||||||||||||||
| TOTAL PH, ID, CVM | |||||||||||||||||||||||
| US | 1,878 | 1,895 | (0.9) | (0.9) | — | ||||||||||||||||||
| Intl | 916 | 952 | (3.6) | (5.5) | 1.9 | ||||||||||||||||||
| WW | 2,795 | 2,846 | (1.8) | (2.4) | 0.6 | ||||||||||||||||||
| TOTAL INNOVATIVE MEDICINE | |||||||||||||||||||||||
| US | 9,979 | 9,161 | 8.9 | 8.9 | — | ||||||||||||||||||
| Intl | 6,405 | 6,041 | 6.0 | 3.6 | 2.4 | ||||||||||||||||||
| WW | $16,384 | 15,202 | 7.8 | % | 6.8 | % | 1.0 | % | |||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SECOND QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2) | |||||||||||||||||||||||
| CARDIOVASCULAR | |||||||||||||||||||||||
| US | $ | 1,426 | 1,364 | 4.5 | % | 4.5 | % | — | % | ||||||||||||||
| Intl | 978 | 948 | 3.2 | 1.1 | 2.1 | ||||||||||||||||||
| WW | 2,404 | 2,313 | 4.0 | 3.1 | 0.9 | ||||||||||||||||||
| ELECTROPHYSIOLOGY | |||||||||||||||||||||||
| US | 783 | 741 | 5.8 | 5.8 | — | ||||||||||||||||||
| Intl | 749 | 728 | 2.9 | 0.4 | 2.5 | ||||||||||||||||||
| WW | 1,533 | 1,468 | 4.4 | 3.1 | 1.3 | ||||||||||||||||||
| ABIOMED | |||||||||||||||||||||||
| US | 342 | 360 | (4.8) | (4.8) | — | ||||||||||||||||||
| Intl | 97 | 89 | 9.5 | 9.2 | 0.3 | ||||||||||||||||||
| WW | 440 | 448 | (2.0) | (2.0) | 0.0 | ||||||||||||||||||
| SHOCKWAVE | |||||||||||||||||||||||
| US | 268 | 233 | 14.6 | 14.6 | — | ||||||||||||||||||
| Intl | 67 | 58 | 14.5 | 15.4 | (0.9) | ||||||||||||||||||
| WW | 335 | 292 | 14.6 | 14.7 | (0.1) | ||||||||||||||||||
| OTHER CARDIOVASCULAR | |||||||||||||||||||||||
| US | 33 | 31 | 5.5 | 5.5 | — | ||||||||||||||||||
| Intl | 65 | 72 | (10.5) | (13.2) | 2.7 | ||||||||||||||||||
| WW | 98 | 104 | (5.7) | (7.5) | 1.8 | ||||||||||||||||||
| SURGERY | |||||||||||||||||||||||
| US | 1,094 | 1,043 | 5.0 | 5.0 | — | ||||||||||||||||||
| Intl | 1,559 | 1,512 | 3.1 | 0.5 | 2.6 | ||||||||||||||||||
| WW | 2,653 | 2,555 | 3.9 | 2.3 | 1.6 | ||||||||||||||||||
| ADVANCED | |||||||||||||||||||||||
| US | 499 | 477 | 4.7 | 4.7 | — | ||||||||||||||||||
| Intl | 691 | 687 | 0.5 | (1.9) | 2.4 | ||||||||||||||||||
| WW | 1,189 | 1,164 | 2.2 | 0.8 | 1.4 | ||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| US | 596 | 567 | 5.2 | 5.2 | — | ||||||||||||||||||
| Intl | 868 | 825 | 5.3 | 2.5 | 2.8 | ||||||||||||||||||
| WW | 1,464 | 1,391 | 5.2 | 3.6 | 1.6 | ||||||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SECOND QUARTER | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2)(Continued) | |||||||||||||||||||||||
| VISION | |||||||||||||||||||||||
| US | $565 | 557 | 1.4 | % | 1.4 | % | — | % | |||||||||||||||
| Intl | 887 | 813 | 9.1 | 8.5 | 0.6 | ||||||||||||||||||
| WW | 1,451 | 1,369 | 6.0 | 5.6 | 0.4 | ||||||||||||||||||
| CONTACT LENSES / OTHER | |||||||||||||||||||||||
| US | 445 | 429 | 3.6 | 3.6 | — | ||||||||||||||||||
| Intl | 580 | 536 | 8.1 | 7.9 | 0.2 | ||||||||||||||||||
| WW | 1,025 | 965 | 6.1 | 6.0 | 0.1 | ||||||||||||||||||
| SURGICAL | |||||||||||||||||||||||
| US | 120 | 128 | (6.0) | (6.0) | — | ||||||||||||||||||
| Intl | 306 | 277 | 10.9 | 9.6 | 1.3 | ||||||||||||||||||
| WW | 426 | 403 | 5.6 | 4.7 | 0.9 | ||||||||||||||||||
| ORTHOPAEDICS | |||||||||||||||||||||||
| US | 1,470 | 1,420 | 3.5 | 3.5 | — | ||||||||||||||||||
| Intl | 948 | 885 | 7.2 | 5.3 | 1.9 | ||||||||||||||||||
| WW | 2,418 | 2,305 | 4.9 | 4.2 | 0.7 | ||||||||||||||||||
| HIPS | |||||||||||||||||||||||
| US | 283 | 271 | 4.6 | 4.6 | — | ||||||||||||||||||
| Intl | 158 | 150 | 5.5 | 3.0 | 2.5 | ||||||||||||||||||
| WW | 441 | 421 | 4.9 | 4.0 | 0.9 | ||||||||||||||||||
| KNEES | |||||||||||||||||||||||
| US | 228 | 226 | 1.1 | 1.1 | — | ||||||||||||||||||
| Intl | 182 | 164 | 11.4 | 10.3 | 1.1 | ||||||||||||||||||
| WW | 410 | 389 | 5.5 | 5.0 | 0.5 | ||||||||||||||||||
| TRAUMA | |||||||||||||||||||||||
| US | 536 | 501 | 6.7 | 6.7 | — | ||||||||||||||||||
| Intl | 291 | 267 | 9.2 | 7.4 | 1.8 | ||||||||||||||||||
| WW | 827 | 768 | 7.6 | 6.9 | 0.7 | ||||||||||||||||||
| SPINE, SPORTS & OTHER | |||||||||||||||||||||||
| US | 423 | 422 | 0.2 | 0.2 | — | ||||||||||||||||||
| Intl | 317 | 305 | 4.0 | 1.9 | 2.1 | ||||||||||||||||||
| WW | 740 | 727 | 1.8 | 0.9 | 0.9 | ||||||||||||||||||
| TOTAL MEDTECH | |||||||||||||||||||||||
| US | 4,554 | 4,383 | 3.9 | 3.9 | — | ||||||||||||||||||
| Intl | 4,372 | 4,158 | 5.2 | 3.2 | 2.0 | ||||||||||||||||||
| WW | $8,926 | 8,541 | 4.5 | % | 3.6 | % | 0.9 | % | |||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SIX MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2) | |||||||||||||||||||||||
| ONCOLOGY | |||||||||||||||||||||||
| US | $7,684 | 6,398 | 20.1 | % | 20.1 | % | — | % | |||||||||||||||
| Intl | 6,695 | 5,592 | 19.7 | 13.2 | 6.5 | ||||||||||||||||||
| WW | 14,379 | 11,990 | 19.9 | 16.9 | 3.0 | ||||||||||||||||||
| DARZALEX | |||||||||||||||||||||||
| US | 4,643 | 3,846 | 20.7 | 20.7 | — | ||||||||||||||||||
| Intl | 3,528 | 2,930 | 20.4 | 13.7 | 6.7 | ||||||||||||||||||
| WW | 8,171 | 6,776 | 20.6 | 17.7 | 2.9 | ||||||||||||||||||
| CARVYKTI | |||||||||||||||||||||||
| US | 905 | 676 | 33.8 | 33.8 | — | ||||||||||||||||||
| Intl | 349 | 132 | * | * | * | ||||||||||||||||||
| WW | 1,254 | 808 | 55.1 | 52.1 | 3.0 | ||||||||||||||||||
| TECVAYLI | |||||||||||||||||||||||
| US | 313 | 219 | 43.1 | 43.1 | — | ||||||||||||||||||
| Intl | 148 | 98 | 51.1 | 45.2 | 5.9 | ||||||||||||||||||
| WW | 462 | 317 | 45.5 | 43.7 | 1.8 | ||||||||||||||||||
| TALVEY | |||||||||||||||||||||||
| US | 213 | 150 | 41.7 | 41.7 | — | ||||||||||||||||||
| Intl | 113 | 42 | * | * | * | ||||||||||||||||||
| WW | 326 | 192 | 69.3 | 67.2 | 2.1 | ||||||||||||||||||
| RYBREVANT / LAZCLUZE | |||||||||||||||||||||||
| US | 365 | 252 | 45.0 | 45.0 | — | ||||||||||||||||||
| Intl | 181 | 69 | * | * | * | ||||||||||||||||||
| WW | 546 | 320 | 70.4 | 69.9 | 0.5 | ||||||||||||||||||
| ERLEADA | |||||||||||||||||||||||
| US | 738 | 670 | 10.2 | 10.2 | — | ||||||||||||||||||
| Intl | 1,206 | 1,009 | 19.4 | 12.5 | 6.9 | ||||||||||||||||||
| WW | 1,944 | 1,679 | 15.8 | 11.6 | 4.2 | ||||||||||||||||||
| IMBRUVICA | |||||||||||||||||||||||
| US | 292 | 474 | (38.4) | (38.4) | — | ||||||||||||||||||
| Intl | 966 | 970 | (0.4) | (6.7) | 6.3 | ||||||||||||||||||
| WW | 1,259 | 1,444 | (12.9) | (17.1) | 4.2 | ||||||||||||||||||
OTHER ONCOLOGY(3) | |||||||||||||||||||||||
| US | 216 | 110 | 94.5 | 94.5 | — | ||||||||||||||||||
| Intl | 203 | 341 | (40.5) | (41.3) | 0.8 | ||||||||||||||||||
| WW | 418 | 452 | (7.4) | (8.0) | 0.6 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SIX MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| IMMUNOLOGY | |||||||||||||||||||||||
| US | $4,227 | 4,701 | (10.1) | % | (10.1) | % | — | % | |||||||||||||||
| Intl | 2,997 | 2,999 | (0.1) | (5.0) | 4.9 | ||||||||||||||||||
| WW | 7,224 | 7,700 | (6.2) | (8.1) | 1.9 | ||||||||||||||||||
| TREMFYA | |||||||||||||||||||||||
| US | 2,507 | 1,395 | 79.7 | 79.7 | — | ||||||||||||||||||
| Intl | 1,147 | 747 | 53.6 | 45.5 | 8.1 | ||||||||||||||||||
| WW | 3,654 | 2,142 | 70.6 | 67.8 | 2.8 | ||||||||||||||||||
| SIMPONI / SIMPONI ARIA | |||||||||||||||||||||||
| US | 529 | 597 | (11.2) | (11.2) | — | ||||||||||||||||||
| Intl | 736 | 753 | (2.3) | (6.9) | 4.6 | ||||||||||||||||||
| WW | 1,265 | 1,349 | (6.2) | (8.8) | 2.6 | ||||||||||||||||||
| REMICADE | |||||||||||||||||||||||
| US | 484 | 597 | (19.0) | (19.0) | — | ||||||||||||||||||
US Exports(4) | 28 | 44 | (37.1) | (37.1) | — | ||||||||||||||||||
| Intl | 248 | 281 | (11.5) | (15.4) | 3.9 | ||||||||||||||||||
| WW | 760 | 922 | (17.6) | (18.7) | 1.1 | ||||||||||||||||||
| STELARA | |||||||||||||||||||||||
| US | 556 | 2,059 | (73.0) | (73.0) | — | ||||||||||||||||||
| Intl | 839 | 1,219 | (31.1) | (34.6) | 3.5 | ||||||||||||||||||
| WW | 1,396 | 3,278 | (57.4) | (58.7) | 1.3 | ||||||||||||||||||
| OTHER IMMUNOLOGY | |||||||||||||||||||||||
| US | 123 | 9 | * | * | — | ||||||||||||||||||
| Intl | 27 | 0 | * | * | * | ||||||||||||||||||
| WW | 150 | 9 | * | * | * | ||||||||||||||||||
| NEUROSCIENCE | |||||||||||||||||||||||
| US | 3,153 | 2,345 | 34.5 | 34.5 | — | ||||||||||||||||||
| Intl | 1,359 | 1,353 | 0.4 | (3.7) | 4.1 | ||||||||||||||||||
| WW | 4,512 | 3,698 | 22.0 | 20.5 | 1.5 | ||||||||||||||||||
| SPRAVATO | |||||||||||||||||||||||
| US | 920 | 642 | 43.4 | 43.4 | — | ||||||||||||||||||
| Intl | 131 | 93 | 41.8 | 31.9 | 9.9 | ||||||||||||||||||
| WW | 1,052 | 734 | 43.2 | 42.0 | 1.2 | ||||||||||||||||||
CAPLYTA(5) | |||||||||||||||||||||||
| US | 631 | 211 | * | * | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 631 | 211 | * | * | — | ||||||||||||||||||
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | |||||||||||||||||||||||
| US | 1,496 | 1,357 | 10.2 | 10.2 | — | ||||||||||||||||||
| Intl | 558 | 537 | 3.7 | (0.1) | 3.8 | ||||||||||||||||||
| WW | 2,053 | 1,895 | 8.4 | 7.3 | 1.1 | ||||||||||||||||||
| CONCERTA / methylphenidate | |||||||||||||||||||||||
| US | 34 | 62 | (45.5) | (45.5) | — | ||||||||||||||||||
| Intl | 248 | 249 | (0.4) | (3.0) | 2.6 | ||||||||||||||||||
| WW | 282 | 312 | (9.5) | (11.5) | 2.0 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SIX MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| OTHER NEUROSCIENCE | |||||||||||||||||||||||
| US | $ | 72 | 73 | (1.1) | % | (1.1) | % | — | % | ||||||||||||||
| Intl | 422 | 474 | (10.9) | (15.1) | 4.2 | ||||||||||||||||||
| WW | 494 | 547 | (9.6) | (13.2) | 3.6 | ||||||||||||||||||
| PULMONARY HYPERTENSION (PH) | |||||||||||||||||||||||
| US | 1,645 | 1,543 | 6.5 | 6.5 | — | ||||||||||||||||||
| Intl | 633 | 595 | 6.4 | 2.3 | 4.1 | ||||||||||||||||||
| WW | 2,278 | 2,138 | 6.5 | 5.4 | 1.1 | ||||||||||||||||||
| UPTRAVI | |||||||||||||||||||||||
| US | 771 | 747 | 3.2 | 3.2 | — | ||||||||||||||||||
| Intl | 206 | 180 | 14.7 | 7.7 | 7.0 | ||||||||||||||||||
| WW | 977 | 927 | 5.4 | 4.0 | 1.4 | ||||||||||||||||||
| OPSUMIT / OPSYNVI | |||||||||||||||||||||||
| US | 849 | 766 | 10.9 | 10.9 | — | ||||||||||||||||||
| Intl | 359 | 339 | 6.1 | 2.7 | 3.4 | ||||||||||||||||||
| WW | 1,208 | 1,104 | 9.4 | 8.4 | 1.0 | ||||||||||||||||||
| OTHER PULMONARY HYPERTENSION | |||||||||||||||||||||||
| US | 25 | 31 | (19.0) | (19.0) | — | ||||||||||||||||||
| Intl | 68 | 77 | (11.5) | (12.3) | 0.8 | ||||||||||||||||||
| WW | 93 | 107 | (13.6) | (14.2) | 0.6 | ||||||||||||||||||
| INFECTIOUS DISEASES (ID) | |||||||||||||||||||||||
| US | 642 | 635 | 1.1 | 1.1 | — | ||||||||||||||||||
| Intl | 1,010 | 971 | 4.1 | (2.5) | 6.6 | ||||||||||||||||||
| WW | 1,652 | 1,605 | 2.9 | (1.1) | 4.0 | ||||||||||||||||||
| EDURANT / rilpivirine | |||||||||||||||||||||||
| US | 10 | 14 | (29.3) | (29.3) | — | ||||||||||||||||||
| Intl | 749 | 704 | 6.4 | (0.3) | 6.7 | ||||||||||||||||||
| WW | 759 | 718 | 5.7 | (0.9) | 6.6 | ||||||||||||||||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||||||||||||||
| US | 630 | 617 | 2.1 | 2.1 | — | ||||||||||||||||||
| Intl | 185 | 183 | 1.2 | (5.6) | 6.8 | ||||||||||||||||||
| WW | 815 | 799 | 1.9 | 0.4 | 1.5 | ||||||||||||||||||
| OTHER INFECTIOUS DISEASES | |||||||||||||||||||||||
| US | 2 | 4 | (51.6) | (51.6) | — | ||||||||||||||||||
| Intl | 76 | 84 | (9.0) | (13.7) | 4.7 | ||||||||||||||||||
| WW | 78 | 88 | (11.1) | (15.5) | 4.4 | ||||||||||||||||||
See footnotes at end of schedule | |||||||||||||||||||||||
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SIX MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
INNOVATIVE MEDICINE SEGMENT(2)(Continued) | |||||||||||||||||||||||
| CARDIOVASCULAR / METABOLISM / OTHER (CVM) | |||||||||||||||||||||||
| US | $ | 1,499 | 1,631 | (8.1) | % | (8.1) | % | — | % | ||||||||||||||
| Intl | 266 | 312 | (14.8) | (19.5) | 4.7 | ||||||||||||||||||
| WW | 1,765 | 1,943 | (9.2) | (9.9) | 0.7 | ||||||||||||||||||
| XARELTO | |||||||||||||||||||||||
| US | 1,306 | 1,311 | (0.3) | (0.3) | — | ||||||||||||||||||
| Intl | — | — | — | — | — | ||||||||||||||||||
| WW | 1,306 | 1,311 | (0.3) | (0.3) | — | ||||||||||||||||||
| OTHER | |||||||||||||||||||||||
| US | 192 | 320 | (39.9) | (39.9) | — | ||||||||||||||||||
| Intl | 266 | 312 | (14.8) | (19.5) | 4.7 | ||||||||||||||||||
| WW | 458 | 632 | (27.5) | (29.8) | 2.3 | ||||||||||||||||||
| TOTAL PH, ID, CVM | |||||||||||||||||||||||
| US | 3,785 | 3,809 | (0.6) | (0.6) | — | ||||||||||||||||||
| Intl | 1,909 | 1,878 | 1.7 | (3.8) | 5.5 | ||||||||||||||||||
| WW | 5,694 | 5,686 | 0.1 | (1.7) | 1.8 | ||||||||||||||||||
| TOTAL INNOVATIVE MEDICINE | |||||||||||||||||||||||
| US | 18,850 | 17,253 | 9.3 | 9.3 | — | ||||||||||||||||||
| Intl | 12,960 | 11,822 | 9.6 | 3.9 | 5.7 | ||||||||||||||||||
| WW | $ | 31,810 | 29,075 | 9.4 | % | 7.1 | % | 2.3 | % | ||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SIX MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2) | |||||||||||||||||||||||
| CARDIOVASCULAR | |||||||||||||||||||||||
| US | $ | 2,825 | 2,625 | 7.6 | % | 7.6 | % | — | % | ||||||||||||||
| Intl | 1,956 | 1,790 | 9.3 | 5.2 | 4.1 | ||||||||||||||||||
| WW | 4,781 | 4,416 | 8.3 | 6.6 | 1.7 | ||||||||||||||||||
| ELECTROPHYSIOLOGY | |||||||||||||||||||||||
| US | 1,519 | 1,425 | 6.6 | 6.6 | — | ||||||||||||||||||
| Intl | 1,502 | 1,366 | 10.0 | 5.6 | 4.4 | ||||||||||||||||||
| WW | 3,022 | 2,791 | 8.3 | 6.2 | 2.1 | ||||||||||||||||||
| ABIOMED | |||||||||||||||||||||||
| US | 731 | 699 | 4.6 | 4.6 | — | ||||||||||||||||||
| Intl | 197 | 170 | 16.1 | 11.4 | 4.7 | ||||||||||||||||||
| WW | 928 | 868 | 6.8 | 5.9 | 0.9 | ||||||||||||||||||
| SHOCKWAVE | |||||||||||||||||||||||
| US | 510 | 439 | 16.1 | 16.1 | — | ||||||||||||||||||
| Intl | 130 | 110 | 17.7 | 17.2 | 0.5 | ||||||||||||||||||
| WW | 640 | 550 | 16.4 | 16.3 | 0.1 | ||||||||||||||||||
| OTHER CARDIOVASCULAR | |||||||||||||||||||||||
| US | 65 | 63 | 3.1 | 3.1 | — | ||||||||||||||||||
| Intl | 127 | 144 | (11.9) | (15.3) | 3.4 | ||||||||||||||||||
| WW | 192 | 207 | (7.4) | (9.7) | 2.3 | ||||||||||||||||||
| SURGERY | |||||||||||||||||||||||
| US | 2,140 | 2,045 | 4.7 | 4.7 | — | ||||||||||||||||||
| Intl | 3,024 | 2,906 | 4.1 | (0.3) | 4.4 | ||||||||||||||||||
| WW | 5,164 | 4,951 | 4.3 | 1.8 | 2.5 | ||||||||||||||||||
| ADVANCED | |||||||||||||||||||||||
| US | 976 | 934 | 4.5 | 4.5 | — | ||||||||||||||||||
| Intl | 1,337 | 1,303 | 2.6 | (1.4) | 4.0 | ||||||||||||||||||
| WW | 2,312 | 2,237 | 3.4 | 1.0 | 2.4 | ||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| US | 1,165 | 1,111 | 4.8 | 4.8 | — | ||||||||||||||||||
| Intl | 1,687 | 1,603 | 5.2 | 0.7 | 4.5 | ||||||||||||||||||
| WW | 2,852 | 2,714 | 5.1 | 2.4 | 2.7 | ||||||||||||||||||
See footnotes at end of schedule
Johnson & Johnson
Segment sales
(Dollars in Millions)
| SIX MONTHS | |||||||||||||||||||||||
| % Change | |||||||||||||||||||||||
| 2026 | 2025 | Reported | Operational(1) | Currency | |||||||||||||||||||
MEDTECH SEGMENT(2)(Continued) | |||||||||||||||||||||||
| VISION | |||||||||||||||||||||||
| US | $1,144 | 1,123 | 1.9 | % | 1.9 | % | — | % | |||||||||||||||
| Intl | 1,672 | 1,526 | 9.6 | 6.7 | 2.9 | ||||||||||||||||||
| WW | 2,816 | 2,648 | 6.3 | 4.6 | 1.7 | ||||||||||||||||||
| CONTACT LENSES / OTHER | |||||||||||||||||||||||
| US | 913 | 881 | 3.7 | 3.7 | — | ||||||||||||||||||
| Intl | 1,081 | 1,003 | 7.7 | 5.0 | 2.7 | ||||||||||||||||||
| WW | 1,994 | 1,884 | 5.8 | 4.4 | 1.4 | ||||||||||||||||||
| SURGICAL | |||||||||||||||||||||||
| US | 231 | 242 | (4.5) | (4.5) | — | ||||||||||||||||||
| Intl | 591 | 523 | 13.1 | 9.8 | 3.3 | ||||||||||||||||||
| WW | 822 | 764 | 7.5 | 5.3 | 2.2 | ||||||||||||||||||
| ORTHOPAEDICS | |||||||||||||||||||||||
| US | 2,905 | 2,804 | 3.6 | 3.6 | — | ||||||||||||||||||
| Intl | 1,896 | 1,742 | 8.9 | 3.9 | 5.0 | ||||||||||||||||||
| WW | 4,801 | 4,546 | 5.6 | 3.7 | 1.9 | ||||||||||||||||||
| HIPS | |||||||||||||||||||||||
| US | 560 | 534 | 4.9 | 4.9 | — | ||||||||||||||||||
| Intl | 317 | 296 | 7.2 | 1.7 | 5.5 | ||||||||||||||||||
| WW | 877 | 830 | 5.7 | 3.8 | 1.9 | ||||||||||||||||||
| KNEES | |||||||||||||||||||||||
| US | 467 | 457 | 2.2 | 2.2 | — | ||||||||||||||||||
| Intl | 363 | 322 | 13.0 | 8.4 | 4.6 | ||||||||||||||||||
| WW | 830 | 778 | 6.7 | 4.8 | 1.9 | ||||||||||||||||||
| TRAUMA | |||||||||||||||||||||||
| US | 1,068 | 1,003 | 6.4 | 6.4 | — | ||||||||||||||||||
| Intl | 592 | 537 | 10.3 | 5.2 | 5.1 | ||||||||||||||||||
| WW | 1,660 | 1,540 | 7.8 | 6.0 | 1.8 | ||||||||||||||||||
| SPINE, SPORTS & OTHER | |||||||||||||||||||||||
| US | 810 | 810 | 0.0 | 0.0 | — | ||||||||||||||||||
| Intl | 624 | 588 | 6.1 | 1.3 | 4.8 | ||||||||||||||||||
| WW | 1,434 | 1,398 | 2.6 | 0.6 | 2.0 | ||||||||||||||||||
| TOTAL MEDTECH | |||||||||||||||||||||||
| US | 9,013 | 8,596 | 4.8 | 4.8 | — | ||||||||||||||||||
| Intl | 8,549 | 7,965 | 7.3 | 3.2 | 4.1 | ||||||||||||||||||
| WW | $17,562 | 16,561 | 6.0 | % | 4.1 | % | 1.9 | % | |||||||||||||||
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
* Percentage greater than 100% or not meaningful
(1)Operational growth excludes the effect of translational currency
(2)Unaudited
(3)Includes the sales of ZYTIGA which were previously disclosed separately
(4)Reported as U.S. sales
(5)Acquired with Intra-Cellular Therapies on April 2, 2025